PURPOSE: To investigate cloning, expression, and mutation analysis of the putative candidate tumor suppressor gene related with nasopharyngeal carcinoma (NPC). METHODS: We studied the expression profiles in the NPC cell line HNE(1) with the normal nasopharyngeal epithelial cell as control by using cDNA array representing 11,000 cDNA clusters. EST W95442 was found down-regulated in HNE(1). Subsequently, the corresponding gene sequence including this EST was established by cDNA cloning and the RACE (rapid amplification of cDNA end) procedure. The expression pattern of this gene was examined by using Northern blot analysis in various human tissues. Furthermore, we screened the mutations of the coding sequence of the gene using reverse transcription-polymerase chain reaction and single-strand conformation polymorphisms (RT-PCR-SSCP) as well as direct sequencing analysis. RESULTS: A novel gene (GenBank accession No. AF462348) was cloned and named NOR(1) standing for oxidored-nitro domain-containing protein 1 (Human Gene Nomenclature Committee-approved symbol). Northern blot analysis revealed that the NOR(1) gene had two transcripts (1.2 kb, 1.6 kb), and expressed ubiquitously in human tissues. Moreover, a Glu58Gly mutation in the exon 1 of NOR(1) was detected in two of 25 NPC biopsies. CONCLUSIONS: We cloned a novel gene NOR(1), and the Glu58Gly polymorphism of NOR(1) may be involved in the development and/or progression of NPC suggesting that NOR(1) could be a candidate tumor repressor gene related with NPC.
PURPOSE: To investigate cloning, expression, and mutation analysis of the putative candidate tumor suppressor gene related with nasopharyngeal carcinoma (NPC). METHODS: We studied the expression profiles in the NPC cell line HNE(1) with the normal nasopharyngeal epithelial cell as control by using cDNA array representing 11,000 cDNA clusters. EST W95442 was found down-regulated in HNE(1). Subsequently, the corresponding gene sequence including this EST was established by cDNA cloning and the RACE (rapid amplification of cDNA end) procedure. The expression pattern of this gene was examined by using Northern blot analysis in various human tissues. Furthermore, we screened the mutations of the coding sequence of the gene using reverse transcription-polymerase chain reaction and single-strand conformation polymorphisms (RT-PCR-SSCP) as well as direct sequencing analysis. RESULTS: A novel gene (GenBank accession No. AF462348) was cloned and named NOR(1) standing for oxidored-nitro domain-containing protein 1 (Human Gene Nomenclature Committee-approved symbol). Northern blot analysis revealed that the NOR(1) gene had two transcripts (1.2 kb, 1.6 kb), and expressed ubiquitously in human tissues. Moreover, a Glu58Gly mutation in the exon 1 of NOR(1) was detected in two of 25 NPC biopsies. CONCLUSIONS: We cloned a novel gene NOR(1), and the Glu58Gly polymorphism of NOR(1) may be involved in the development and/or progression of NPC suggesting that NOR(1) could be a candidate tumor repressor gene related with NPC.
Authors: J A Plumb; A Bilsland; R Kakani; J Zhao; R M Glasspool; R J Knox; T R Evans; W N Keith Journal: Oncogene Date: 2001-11-22 Impact factor: 9.867
Authors: P P Claudio; C M Howard; Y Fu; C Cinti; L Califano; P Micheli; E W Mercer; M Caputi; A Giordano Journal: Cancer Res Date: 2000-01-01 Impact factor: 12.701
Authors: M H Ward; W H Pan; Y J Cheng; F H Li; L A Brinton; C J Chen; M M Hsu; I H Chen; P H Levine; C S Yang; A Hildesheim Journal: Int J Cancer Date: 2000-06-01 Impact factor: 7.396
Authors: Stephen Safe; Un-Ho Jin; Benjamin Morpurgo; Ala Abudayyeh; Mandip Singh; Ronald B Tjalkens Journal: J Steroid Biochem Mol Biol Date: 2015-04-23 Impact factor: 4.292
Authors: Jaroslav Jelinek; Vazganush Gharibyan; Marcos R H Estecio; Kimie Kondo; Rong He; Woonbok Chung; Yue Lu; Nianxiang Zhang; Shoudan Liang; Hagop M Kantarjian; Jorge E Cortes; Jean-Pierre J Issa Journal: PLoS One Date: 2011-07-08 Impact factor: 3.240